NASDAQ:FENC Fennec Pharmaceuticals (FENC) Stock Price, News & Analysis $5.58 -0.05 (-0.89%) (As of 11:12 AM ET) Add Compare Share Share Today's Range$5.58▼$5.7350-Day Range$5.33▼$6.8852-Week Range$5.00▼$11.92Volume11,625 shsAverage Volume121,644 shsMarket Capitalization$152.49 millionP/E Ratio186.00Dividend YieldN/APrice Target$14.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Fennec Pharmaceuticals alerts: Email Address Fennec Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside160.5% Upside$14.67 Price TargetShort InterestBearish8.52% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.18Based on 17 Articles This WeekInsider TradingSelling Shares$53,603 Sold Last QuarterProj. Earnings Growth41.67%From $0.36 to $0.51 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.65 out of 5 starsMedical Sector428th out of 924 stocksBiological Products, Except Diagnostic Industry60th out of 145 stocks 3.5 Analyst's Opinion Consensus RatingFennec Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageFennec Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.Read more about Fennec Pharmaceuticals' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted8.52% of the float of Fennec Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverFennec Pharmaceuticals has a short interest ratio ("days to cover") of 14.3, which indicates bearish sentiment.Change versus previous monthShort interest in Fennec Pharmaceuticals has recently decreased by 0.51%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldFennec Pharmaceuticals does not currently pay a dividend.Dividend GrowthFennec Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for FENC. Previous Next 2.1 News and Social Media Coverage News SentimentFennec Pharmaceuticals has a news sentiment score of -0.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 17 news articles for Fennec Pharmaceuticals this week, compared to 2 articles on an average week.Search Interest5 people have searched for FENC on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.MarketBeat Follows1 people have added Fennec Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Fennec Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $53,603.00 in company stock.Percentage Held by Insiders10.98% of the stock of Fennec Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions55.51% of the stock of Fennec Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Fennec Pharmaceuticals' insider trading history. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Fennec Pharmaceuticals are expected to grow by 41.67% in the coming year, from $0.36 to $0.51 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Fennec Pharmaceuticals is 187.67, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 145.07.Price to Earnings Ratio vs. SectorThe P/E ratio of Fennec Pharmaceuticals is 187.67, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 139.67.Read more about Fennec Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTIAir Force quietly working with sub $10 stock on new techThere is a little-known energy technology stock that has made an incredible breakthrough… Which could become crucial to the operations of the US Military. And right now there are plans for this stock to undertake a major test project at a US Air Force based in Alaska. Now, this incredible breakthrough is still in its earliest stages… Which means you still have a chance to get in while its trading for under $10.You need to check out the full story right here. About Fennec Pharmaceuticals Stock (NASDAQ:FENC)Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.Read More FENC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart FENC Stock News HeadlinesAugust 4, 2024 | insidertrades.comFennec Pharmaceuticals Inc (NASDAQ:FENC) CEO Sells $15,193.75 in StockAugust 21 at 8:15 PM | finance.yahoo.comFennec Pharmaceuticals Inc. (NASDAQ:FENC) Analysts Are Reducing Their Forecasts For This YearAugust 22, 2024 | DTI (Ad)Air Force quietly working with sub $10 stock on new techThere is a little-known energy technology stock that has made an incredible breakthrough… Which could become crucial to the operations of the US Military. And right now there are plans for this stock to undertake a major test project at a US Air Force based in Alaska. Now, this incredible breakthrough is still in its earliest stages… Which means you still have a chance to get in while its trading for under $10.August 17, 2024 | americanbankingnews.comFennec Pharmaceuticals (NASDAQ:FENC) PT Lowered to $15.00 at Craig HallumAugust 17, 2024 | americanbankingnews.comFennec Pharmaceuticals Inc (NASDAQ:FENC) to Post Q3 2024 Earnings of ($0.18) Per Share, Capital One Financial ForecastsAugust 16, 2024 | americanbankingnews.comFY2027 Earnings Estimate for Fennec Pharmaceuticals Inc Issued By Capital One Financial (NASDAQ:FENC)August 15, 2024 | uk.finance.yahoo.comFennec Pharmaceuticals Second Quarter 2024 Earnings: Misses ExpectationsAugust 15, 2024 | markets.businessinsider.comBuy Rating for Fennec Pharmaceuticals Bolstered by Pedmark’s Market Expansion and New LeadershipAugust 22, 2024 | DTI (Ad)Air Force quietly working with sub $10 stock on new techThere is a little-known energy technology stock that has made an incredible breakthrough… Which could become crucial to the operations of the US Military. And right now there are plans for this stock to undertake a major test project at a US Air Force based in Alaska. Now, this incredible breakthrough is still in its earliest stages… Which means you still have a chance to get in while its trading for under $10.August 15, 2024 | americanbankingnews.comQ3 2024 EPS Estimates for Fennec Pharmaceuticals Inc (NASDAQ:FENC) Lowered by WedbushAugust 15, 2024 | markets.businessinsider.comOptimistic Buy Rating for Fennec Pharmaceuticals Amidst Pedmark’s Market Expansion and Strong Financial OutlookAugust 14, 2024 | gurufocus.comQ2 2024 Fennec Pharmaceuticals Inc Earnings Call TranscriptAugust 14, 2024 | americanbankingnews.comFY2026 Earnings Forecast for Fennec Pharmaceuticals Inc (NASDAQ:FENC) Issued By WedbushAugust 14, 2024 | americanbankingnews.comFennec Pharmaceuticals' (FENC) "Outperform" Rating Reaffirmed at WedbushAugust 14, 2024 | finance.yahoo.comQ2 2024 Fennec Pharmaceuticals Inc Earnings CallAugust 13, 2024 | globenewswire.comFennec Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business UpdateAugust 7, 2024 | markets.businessinsider.comBuy Rating Affirmed Amid Leadership Transition and Strong Growth Prospects for Fennec PharmaceuticalsAugust 7, 2024 | investing.comFennec Pharmaceuticals names new CEO to expand PEDMARK reachSee More Headlines Receive FENC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Fennec Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/13/2024Today8/22/2024Next Earnings (Estimated)11/04/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:FENC CUSIPN/A CIK1211583 Webwww.fennecpharma.com Phone919-636-4530Fax919-890-0490EmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Target$14.00 High Stock Price Target$15.00 Low Stock Price Target$13.00 Potential Upside/Downside+162.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)$0.03 Trailing P/E Ratio186.00 Forward P/E Ratio15.50 P/E GrowthN/ANet Income$-16,050,000.00 Net Margins6.33% Pretax Margin6.32% Return on Equity-39.41% Return on Assets8.46% Debt Debt-to-Equity Ratio9.86 Current Ratio6.93 Quick Ratio6.72 Sales & Book Value Annual Sales$48.89 million Price / Sales3.12 Cash FlowN/A Price / Cash FlowN/A Book Value($0.43) per share Price / Book-12.98Miscellaneous Outstanding Shares27,328,000Free Float24,327,000Market Cap$152.49 million OptionableOptionable Beta0.29 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Rostislav Raykov (Age 42)Pres, CEO & Director Mr. Robert C. Andrade (Age 43)Chief Financial Officer Mr. Mark GowlandControllerMr. Lei FangPres of Pharstat IncMs. Anne McKay (Age 64)Regulatory Consultant Key CompetitorsREGENXBIONASDAQ:RGNXProKidneyNASDAQ:PROKiTeos TherapeuticsNASDAQ:ITOSValnevaNASDAQ:VALNAnavex Life SciencesNASDAQ:AVXLView All CompetitorsInsiders & InstitutionsThe Manufacturers Life Insurance Company Bought 11,310 shares on 8/15/2024Ownership: 0.041%WINTON GROUP LtdBought 67,005 shares on 8/9/2024Ownership: 0.245%Acadian Asset Management LLCBought 8,086 shares on 8/6/2024Ownership: 0.030%Rosty RaykovSold 2,431 sharesTotal: $15,193.75 ($6.25/share)Rhumbline AdvisersBought 8,987 shares on 8/1/2024Ownership: 0.107%View All Insider TransactionsView All Institutional Transactions FENC Stock Analysis - Frequently Asked Questions How have FENC shares performed this year? Fennec Pharmaceuticals' stock was trading at $11.22 on January 1st, 2024. Since then, FENC stock has decreased by 49.8% and is now trading at $5.63. View the best growth stocks for 2024 here. How were Fennec Pharmaceuticals' earnings last quarter? Fennec Pharmaceuticals Inc (NASDAQ:FENC) announced its earnings results on Tuesday, August, 13th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.06 by $0.26. The company earned $7.26 million during the quarter, compared to analyst estimates of $13.67 million. Fennec Pharmaceuticals had a negative trailing twelve-month return on equity of 39.41% and a net margin of 6.33%. Who are Fennec Pharmaceuticals' major shareholders? Top institutional investors of Fennec Pharmaceuticals include Bank of New York Mellon Corp (0.25%), WINTON GROUP Ltd (0.25%), Rhumbline Advisers (0.11%) and The Manufacturers Life Insurance Company (0.04%). Insiders that own company stock include Rosty Raykov, Robert Andrade, Chris A Rallis and Adrian Haigh. View institutional ownership trends. How do I buy shares of Fennec Pharmaceuticals? Shares of FENC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Fennec Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Fennec Pharmaceuticals investors own include Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), Pfizer (PFE), Amarin (AMRN), VBI Vaccines (VBIV), Gilead Sciences (GILD) and Trevena (TRVN). This page (NASDAQ:FENC) was last updated on 8/22/2024 by MarketBeat.com Staff From Our PartnersWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | SponsoredAir Force quietly working with sub $10 stock on new techThere is a little-known energy technology stock that has made an incredible breakthrough… Which could becom...DTI | SponsoredMillionaire Investor Warns: “Brace for Apple Collapse”Apple stock has quadrupled over the past five years. But now even Warren Buffett is pulling the plug. The O...Stansberry Research | SponsoredTrump is sounding the alarmEurope is one of the latest to release a central bank digital currency and along with it, new cash rules. Chri...Preserve Gold | SponsoredUS developing “superweapon” to defeat China and Russia?Our new superweapon is a gift to every patriot. I predict the devastating new tech behind this weapon will cre...Paradigm Press | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | SponsoredAmazon coin set to soar 25X – starting August 19thChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fennec Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Fennec Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free FENC Stock Alerts